Alvotech Q1 2026 Financial Results
Alvotech reported Q1 2026 revenue of $105.9 million, down from $132.8 million in the prior year, with Adjusted EBITDA of $24.4 million and a gross margin of 57%. The decline was attributed to a deliberate production slowdown to improve quality systems and de-risk future regulatory submissions, with a recovery expected as operations resume. Management maintained its full-year 2026 guidance for revenue of $650-$700 million and Adjusted EBITDA of $180-$220 million, while confirming plans to resubmit pending BLAs to the FDA in the second quarter.
Key figures
- Revenue
- 105900000
- Guidance
- 2026 revenue $650-$700 million, Adjusted EBITDA $180-$220 million
- Revenue Yoy
- -20%
- Gross margin
- 57%
- Adjusted ebitda
- 24400000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.